Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Lymphoma | Research

The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study

Authors: Kexin Feng, Shuangtao Zhao, Qingyao Shang, Guangdong Qiao, Jiaxiang Liu, Chenxuan Yang, Ya Wei, Yalun Li, Fei Ren, Lixue Xuan, Xiang Wang, Xin Wang

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Background

Due to the rarity of PBL and the lack of large-scale studies, the prognostic value of IPI in PBL was controversial. Especially in the rituximab era, the ability of IPI to stratify prognosis in patients receiving immunochemotherapy was severely reduced. Then revised IPI (R-IPI) and National Comprehensive Cancer Network IPI (NCCN-IPI) were introduced. The present study aimed to evaluate the prognostic value of IPI and the other IPIs in patients with PBL in a Chinese population.

Methods

We performed a multicenter retrospective study of 71 patients with PBL from 3 institutions in China. The Kaplan–Meier method and log-rank tests were used for the survival analysis. Cox regression analysis was performed to evaluate the prognostic factors. Subgroup analysis was performed to assess the prognostic significance of IPI scores, R-IPI scores, and NCCN-IPI scores.

Results

The median follow-up was 4.7 years (0.7–21.8 years). The 5-year progression-free survival (PFS) and overall survival (OS) rates were 90.2% and 96.3%. In the multivariate analysis, only IPI scores and radiotherapy were significantly associated with OS and PFS (P < 0.05). Applying the R-IPI in our patient cohort indicates a significant difference in PFS between the two groups of R-IPI (P = 0.034) but not for OS (P = 0.072). And the NCCN-IPI was prognostic for OS (P = 0.025) but not for PFS (P = 0.066). Subgroup analyses of IPI showed that survival analysis of IPI scores for the PFS and OS of patients using rituximab were not significantly different (P > 0.05).

Conclusions

Our study confirms the prognostic value of IPI in patients with PBL, but the predictive value of IPI proved to be relatively low with the addition of the rituximab. The R-IPI and NCCN-IPI can accurately assess the high and low-risk groups of PBL patients but were insufficient to evaluate the intermediate risk group.
Appendix
Available only for authorised users
Literature
1.
2.
Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol. 2013;24(9):2236–44.CrossRefPubMed
3.
Domchek SM, Hecht JL, Fleming MD, Pinkus GS, Canellos GP. Lymphomas of the breast: primary and secondary involvement. Cancer. 2002;94(1):6–13.CrossRefPubMed
4.
5.
Raj SD, Shurafa M, Shah Z, Raj KM, Fishman MDC, Dialani VM. Primary and secondary breast lymphoma: clinical, pathologic, and multimodality imaging review. Radiographics. 2019;39(3):610–25.CrossRefPubMed
6.
Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the international extranodal lymphoma study group. Ann Oncol. 2008;19(2):233–41.CrossRefPubMed
7.
Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2012;103(2):245–51.CrossRefPubMed
8.
Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirani R, Evens AM, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014;165(3):358–63.CrossRefPubMedPubMedCentral
9.
Hu S, Song Y, Sun X, Su L, Zhang W, Jia J, Bai O, Yang S, Liang R, Li X, et al. Primary breast diffuse large B-cell lymphoma in the rituximab era: therapeutic strategies and patterns of failure. Cancer Sci. 2018;109(12):3943–52.CrossRefPubMedPubMedCentral
10.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.CrossRefPubMed
11.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.CrossRefPubMed
12.
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42.CrossRefPubMedPubMedCentral
13.
Lin YC, Tsai CH, Wu JS, Huang CS, Kuo SH, Lin CW, Cheng AL. Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast–a review of 42 primary and secondary cases in Taiwanese patients. Leuk Lymphoma. 2009;50(6):918–24.CrossRefPubMed
14.
Seker M, Bilici A, Ustaalioglu BO, Yilmaz B, Ozturk B, Ünal A, Dane F, Ozdemir NY, Elkiran ET, Kalender ME, et al. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast. Arch Gynecol Obstet. 2011;284(2):405–9.CrossRefPubMed
15.
Shao YB, Sun XF, He YN, Liu CJ, Liu H. Clinicopathological features of thirty patients with primary breast lymphoma and review of the literature. Med Oncol. 2015;32(2):448.CrossRefPubMed
16.
Luo H, Yi P, Wang W, Li K, Meng L, Li J, Zeng W, Tang M. Clinicopathological features, treatment, and prognosis in primary diffuse large B cell lymphoma of the breast: a retrospective study of 46 patients. Med Sci Monit. 2019;25:8671–82.CrossRefPubMedPubMedCentral
17.
Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer. 2014;111(1):55–60.CrossRefPubMedPubMedCentral
18.
Prochazka KT, Melchardt T, Posch F, Schlick K, Deutsch A, Beham-Schmid C, Weiss L, Gary T, Neureiter D, Klieser E, et al. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. Br J Cancer. 2016;115(10):1264–72.CrossRefPubMedPubMedCentral
19.
Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin. Br J Haematol. 2015;168(2):239–45.CrossRefPubMed
20.
Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, et al. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol. 2015;95(6):538–44.CrossRefPubMed
21.
Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Schlick K, Huemer F, Deutsch A, Neumeister P, et al. Independent prognostic value of serum markers in diffuse large B-cell lymphoma in the era of the NCCN-IPI. J Natl Compr Canc Netw. 2015;13(12):1501–8.CrossRefPubMed
22.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-airlie house, virginia, November 1997. J Clin Oncol. 1999;17(12):3835–49.CrossRefPubMed
23.
Jia Y, Sun C, Liu Z, Wang W, Zhou X. Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. Oncotarget. 2018;9(3):3956–67.CrossRefPubMed
24.
Sun Y, Joks M, Xu LM, Chen XL, Qian D, You JQ, Yuan ZY. Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes. Onco Targets Ther. 2016;9:2069–80.CrossRefPubMedPubMedCentral
25.
Genco IS, Gur H, Hajiyeva S. Lymphoma of the breast: a clinicopathologic analysis of 51 cases with a specific emphasis on patients with a history of breast carcinoma. Breast J. 2021;27(5):456–60.CrossRefPubMed
26.
Martinelli G, Ryan G, Seymour JF, Nassi L, Steffanoni S, Alietti A, Calabrese L, Pruneri G, Santoro L, Kuper-Hommel M, et al. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the international extranodal lymphoma study group. Ann Oncol. 2009;20(12):1993–9.CrossRefPubMed
27.
Valente I, Cantergiani F, Rinaldi A, Russo F, Mancini C, D’Aloia C. Primitive marginal lymphoma of the breast. Breast J. 2020;26(4):790–1.CrossRefPubMed
28.
Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S. Non-Hodgkin lymphoma of the breast. Cancer. 2007;110(1):25–30.CrossRefPubMed
29.
Miyoshi I, Yamamoto K, Saito T, Taguchi H. Burkitt lymphoma of the breast. Am J Hematol. 2006;81(2):147–8.CrossRefPubMed
30.
31.
Avilés A, Castañeda C, Neri N, Cleto S, Nambo MJ. Rituximab and dose dense chemotherapy in primary breast lymphoma. Haematologica. 2007;92(8):1147–8.CrossRefPubMed
32.
Liu PP, Wang KF, Jin JT, Bi XW, Sun P, Wang Y, Yang H, Li ZM, Jiang WQ, Xia Y. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis. Cancer Med. 2018;7(5):1845–51.CrossRefPubMedPubMedCentral
33.
Lin Y, Guo XM, Shen KW, Wang JL, Jiang GL. Primary breast lymphoma: long-term treatment outcome and prognosis. Leuk Lymphoma. 2006;47(10):2102–9.CrossRefPubMed
34.
Zhang T, Zhang Y, Fei H, Shi X, Wang L, Wang P, Yu J, Shen Y, Feng S. Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience. Cancer Cell Int. 2021;21(1):498.CrossRefPubMedPubMedCentral
35.
Yhim HY, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, Eom HS, Kim JA, Lee JH, Won JH, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer. 2012;131(1):235–43.CrossRefPubMed
36.
Zhao P, Zhu L, Song Z, Wang X, Ma W, Zhu X, Qiu L, Li L, Zhou S, Qian Z, et al. Combination of baseline total metabolic tumor volume measured on FDG-PET/CT and β2-microglobulin have a robust predictive value in patients with primary breast lymphoma. Hematol Oncol. 2020;38(4):493–500.CrossRefPubMed
37.
Ou CW, Shih LY, Wang PN, Chang H, Kuo MC, Tang TC, Wu JH, Lin TL, Hung YS, Dunn P. Primary breast lymphoma: a single-institute experience in Taiwan. Biomed J. 2014;37(5):321–5.CrossRefPubMed
38.
Zhang N, Cao C, Zhu Y, Liu P, Liu L, Lu K, Luo J, Zhou N. Primary breast diffuse large B-cell lymphoma in the era of rituximab. Onco Targets Ther. 2016;9:6093–7.CrossRefPubMedPubMedCentral
Metadata
Title
The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study
Authors
Kexin Feng
Shuangtao Zhao
Qingyao Shang
Guangdong Qiao
Jiaxiang Liu
Chenxuan Yang
Ya Wei
Yalun Li
Fei Ren
Lixue Xuan
Xiang Wang
Xin Wang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02772-y

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Primary research

MeCP2 confers 5-fluorouracil resistance in gastric cancer via upregulating the NOX4/PKM2 pathway

Research

Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characterization in ovarian cancer

Correction

Correction to: Exosomal lncRNA SNHG10 derived from colorectal cancer cells suppresses natural killer cell cytotoxicity by upregulating INHBC

Primary research

Construction and validation of a ferroptosis-related long noncoding RNA signature in clear cell renal cell carcinoma

Primary research

SLC4A4 promotes prostate cancer progression in vivo and in vitro via AKT-mediated signalling pathway

Primary research

Knockdown of RSPH14 inhibits proliferation, migration, and invasion and promotes apoptosis of hepatocellular carcinoma via RelA
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits